<DOC>
	<DOCNO>NCT01577550</DOCNO>
	<brief_summary>Safety , tolerability efficacy BI 655066 male female patient moderate severe psoriasis .</brief_summary>
	<brief_title>Single Rising Dose Study BI 655066 Patients With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient age 1875 year ( inclusive ) 2 . Chronic moderate severe plaque psoriasis last = &gt; 6 month involvement Body Surface Area ( BSA ) = &gt; 10 % , Psoriasis Area Severity Index ( PASI ) = &gt; 12 Static Physician Global Assessment ( sPGA ) score moderate 3 . Body Mass Index ( BMI ) = &gt; 18.5 &lt; 40 kg/m2 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 5 . Female patient must childbearing potential ( i.e. , must postmenopausal surgically sterilize ) must negative pregnancy test screening . Exclusion criterion : 1 . Evidence current previous clinically significant disease , medical condition psoriasis , find medical examination ( include vital sign Electrocardiogram ( ECG ) ) , opinion Investigator , would compromise safety patient quality data . This criterion provide opportunity investigator exclude patient base clinical judgment , even eligibility criterion satisfy ( Psoriatic arthritis consider exclusion . ) 2 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder , diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder , chronic relevant acute infection include hepatitis tuberculosis ( positive interferongamma release assay screen ) history orthostatic hypotension , faint spell blackout , investigator 's judgement , could jeopardize safe conduct study 3 . History allergy/hypersensitivity systemically administer biologic agent excipients 4 . Use biologic agent psoralen ultraviolet A ( PUVA ) within 12 week prior Visit 2 , ultraviolet B ( UVB ) phototherapy oral antipsoriatic medication within 4 week prior Visit 2 , topical antipsoriasis medication ( except emollient ) within 2 week prior Visit 2 5 . Use ustekinumab within 24 week prior Visit 2 6 . Had prior treatment psoriasis biologics inadequate clinical response therapy assess dermatologist investigator 7 . Intake restrict medication drug consider likely interfere safe conduct study 8 . Use drug might reasonably influence result trial prolong QT/QTc interval within 10 day prior administration trial 9 . Participation another trial investigational drug within 4 week 5 halflives ( whichever great ) precede Visit 2 10 . History alcohol abuse within last 12 month ( intake 30 g/day ) 11 . History drug abuse within last 12 month positive drug screen screen Visit 2 12 . Any blood donation significant blood loss within 4 week prior Visit 2 13 . Unwilling capable abstain alcoholic beverage one day prior two day Visit 2 14 . Excessive physical activity ( within 1 week prior Visit 2 ) 15 . Any laboratory value screen visit outside reference range clinical relevance base physician investigator judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>